United States· US:0378-6955_43459ab6-17fd-4c77-b269-4a97780af170

Bexarotene

A bexarotene product containing bexarotene, registered in United States by Mylan Pharmaceuticals Inc.. The same ATC class is registered in 13 of our 19 countries.

ATC L01XF03US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedBexaroteneATCL01XF03REGISTER NO.US:0378-6955_43459ab6…PACKS LISTED2CHECKEDSeptember 13, 2026

Where it is registered

Bexarotene is registered in 13 of 19 countries.

Countries holding a registration under ATC L01XF03 (bexarotene), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 8 of them publish a price we can compare per daily dose

Bexarotene · ATC L01XF03

13 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
BEXAROTENE
Manufacturer
Mylan Pharmaceuticals Inc.
Country
United States (US)
ATC code
L01XF03
ATC class
Bexarotene
Defined daily dose
0.54 g, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 13, 2026

Packs & prices · 2

  • ndc11
    0378-6955-01
  • ndc11
    0378695501
    100 CAPSULE, LIQUID FILLED in 1 BOTTLE, PLASTIC (0378-6955-01)

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

573 interactions on record for bexarotene.

Graded by severity as the source publishes them — 127 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Bexarotene · interactions on record

573 records

  • 127 severe
  • 357 moderate
  • 80 minor
  • 9 info

Most severe, free to view

  • EluxadolineA07DA06severe
  • LiraglutidA08AX02severe
  • SemaglutidA08AX03severe
  • SitagliptinA10BH01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Bexarotene in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All bexarotene products

Authorised across Europe · EMA

The same active substance is authorised in 12 EEA countries. Names it is sold under:

  • Austria · Bexagia
  • Germany · Bexaroten Cipla
  • Denmark · Bexarotene
  • Spain · Bexaroteno Cipla
  • Finland · Bexarotene Amdipharm
  • France · Bexarotene Cipla
  • United Kingdom (Northern Ireland) · Bexarotene Genus Pharmaceuticals Ltd.
  • Iceland · Targretin
  • Italy · Bexarotene Cipla
  • Liechtenstein · Targretin
  • Norway · Bexarotene Amdipharm, Targretin
  • Sweden · Bexarotene Amdipharm

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ac6c5f1c-8b72-414b-a275-7bea349e1d2b
GET /v1/drugs/ac6c5f1c-8b72-414b-a275-7bea349e1d2b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "75",
  "substance": "BEXAROTENE",
  "productndc": "0378-6955",
  "dosage_form": "CAPSULE, LIQUID FILLED",
  "dea_schedule": null,
  "strength_unit": "mg/1",
  "application_number": "ANDA203174",
  "marketing_category": "ANDA"
}

See everything about bexarotene.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.